Previous 10 | Next 10 |
4 Penny Stocks to Add to Your Watchlist Right Now After a more than shaky week of trading for both penny stocks and blue chips, investors are excited to get another week up and going. But, to make money with penny stocks , traders need to do two things. First and foremost, investors...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It’s time to dive into another day of investing with the biggest pre-market stock movers for Thursday! Source: f11photo/Shutterstock.com Moving stocks this morning are FDA updates, merge...
MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will...
Baudax Bio (NASDAQ:BXRX) has lost ~24.5% in the pre-market after the company announced an agreement to issue and sell convertible preferred stock and warrants for the purchase of ~12.7M shares of common stock for ~$4.2M gross proceeds. According to its agreement signed with certain ...
MALVERN, Pa., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that it has entered into a definitive agreement with ...
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will part...
BX-1000 Completes Dose-Escalation Study; Was Generally Well Tolerated and Rapidly Achieved Muscle Paralysis, Along with Complete Spontaneous Recovery BX-2000 and BX-3000 to Advance Into Clinical Studies in 2022 MALVERN, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc....
Baudax Bio, Inc. (BXRX) Q3 2021 Earnings Conference Call November 04, 2021 08:00 AM ET Company Participants Claudia Styslinger - Investor Relations Gerri Henwood - President & Chief Executive Officer Rick Casten - Chief Financial Officer Conference Call Participants David Amsellem - Piper...
Baudax Bio (NASDAQ:BXRX): Q3 GAAP EPS of -$0.20 misses by $0.05. Revenue of $0.28M (+300.0% Y/Y) misses by $0.32M. Shares +0.18% PM. Press Release As of September 30, 2021, Baudax Bio had cash, cash equivalents and short-term investments of $24.9 million. Adjusted net loss for the t...
ANJESO ® Revenue Up 40% in Q3 2021 over Q2 2021 and Up Over 300% in Q3 2021 over Q3 2020 Solid Growth in End User Demand Units, September 2021 Strongest Month Launch-to-Date, Indicating Growing Adoption of ANJESO Neuromuscular Blocking Agent BX1000 Compl...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023